Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, today announced the acquisition of Spiegelberg GmbH & Co. KG (Spiegelberg), an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital. Following the acquisition, the companies will combine their product suites, manufacturing, and distribution channels to optimize their strengths aiming at becoming a global leader in providing innovative next-generation brain monitoring devices. Spiegelberg has developed an internationally recognized, strong brand for its innovative neurosurgical devices and consumables and is a leading manufacturer of probes for intracranial pressure (ICP) measurement. The company works with recognized research institutes, leading clinics, and specialists in neurosurgery to develop products that are best tailored to the patient. Luciole Medical will leverage Spiegelberg’s manufacturing, regulatory, and commercial capabilities, including its global supply network, to bring improved brain monitoring devices to a broad patient population. Spiegelberg’s recognized ICP monitors and wide-reaching sales channels that span neuroclinics, hospitals, and special distributors highly complement Luciole’s easy-to-use, minimally invasive, next-generation brain monitoring solutions and non-invasive patch. Under Luciole’s leadership, the two companies will be in the position to individualize and optimize comprehensive brain monitoring devices on an international scale. "We have known the Spiegelberg team and products for a long time and were impressed by the quality of the business they have built. This strategic acquisition will allow us to accelerate the accessibility of our products in Europe and prepare for the market launch of our innovative brain monitoring technologies in the US. We at Luciole believe that brain monitoring is an important tool both in the operating room and the intensive care setting to understand the pathologies linked to a fundamental but poorly understood organ," said Luciole CEO, Dr. Philippe Dro. "Joining forces with Luciole Medical AG will allow us to offer an extensive range of truly innovative products to our large and growing network of clinicians, partners, and distributors, which will benefit both patients and clinicians and improve neurosurgery outcomes. We are looking forward to this next stage of our development," added Spiegelberg CEO, Stefan Paschko.